More Articles

Radical treatments for difficult times Pharma News | Posted 30/07/2009

The economic downturn is only one of many factors forcing the drug industry to rethink its strategy reported Financial Times pharmaceuticals correspondent Mr Andrew Jack in the British Medical Jour...

The economics of follow-on drug research and development Biosimilars/Research | Posted 30/07/2009

The development of so-called ‘me-too’ or ‘follow-on’ drugs by the pharmaceutical industry has been viewed by some as duplicative and wasteful, while others have argued that these drugs often provid...

Shifting paradigms: biopharmaceuticals versus low molecular weight drugs Biosimilars/Research | Posted 30/07/2009

Biopharmaceuticals are pharmaceutical products consisting of (glyco)proteins. Nowadays a substantial part of the FDA-approved drugs belong to this class of drugs.

Rejected biosimilars: the Biferonex case Biosimilars/Research | Posted 30/07/2009

On 19 February 2009, the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommended refusal of the marketing authorisation for the medicinal product Biferonex intended for the tr...

Rejected biosimilars: the Insulin Human Rapid Marvel case Biosimilars/Research | Posted 30/07/2009

On 20 December 2007, Marvel LifeSciences Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) of the EMEA that it wished to withdraw its applications for marketing auth...

Rejected biosimilars: the Alpheon case Biosimilars/Research | Posted 30/07/2009

On 28 June 2006 the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommended the refusal of marketing authorisation for Alpheon (interferon alfa-2a), which was intended for the...

Indian Reliance Life Sciences to launch four more biosimilars by next year Biosimilars/News | Posted 30/07/2009

Reliance Life Sciences, based in Mumbai, India, announced on 29 March 2009 in the Indian Business Standard that it will launch four biosimilars by next year.

Indian firms may well take large slice of global biosimilars pie Biosimilars/News | Posted 30/07/2009

Since the Indian government announced that it wants to make almost US$70 million (Euros 49.7 million) in funding available for the development of biosimilar medicines, Indian generics firms adapt t...